- Home
- GOSS vs TSI Comparison
GOSS vs TSI Comparison
Compare GOSS & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- TSI
- Stock Information
- Founded
- GOSS 2015
- TSI 1987
- Country
- GOSS United States
- TSI United States
- Employees
- GOSS N/A
- TSI N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- TSI Investment Managers
- Sector
- GOSS Health Care
- TSI Finance
- Exchange
- GOSS Nasdaq
- TSI Nasdaq
- Market Cap
- GOSS 212.9M
- TSI 241.8M
- IPO Year
- GOSS 2019
- TSI N/A
- Fundamental
- Price
- GOSS $0.81
- TSI $5.01
- Analyst Decision
- GOSS Strong Buy
- TSI
- Analyst Count
- GOSS 5
- TSI 0
- Target Price
- GOSS $9.20
- TSI N/A
- AVG Volume (30 Days)
- GOSS 2.3M
- TSI 106.8K
- Earning Date
- GOSS 11-07-2024
- TSI 01-01-0001
- Dividend Yield
- GOSS N/A
- TSI 7.46%
- EPS Growth
- GOSS N/A
- TSI N/A
- EPS
- GOSS N/A
- TSI N/A
- Revenue
- GOSS $105,322,000.00
- TSI N/A
- Revenue This Year
- GOSS N/A
- TSI N/A
- Revenue Next Year
- GOSS N/A
- TSI N/A
- P/E Ratio
- GOSS N/A
- TSI N/A
- Revenue Growth
- GOSS N/A
- TSI N/A
- 52 Week Low
- GOSS $0.50
- TSI $4.48
- 52 Week High
- GOSS $1.60
- TSI $4.87
- Technical
- Relative Strength Index (RSI)
- GOSS 49.87
- TSI 50.11
- Support Level
- GOSS $0.76
- TSI $4.98
- Resistance Level
- GOSS $0.88
- TSI $5.07
- Average True Range (ATR)
- GOSS 0.08
- TSI 0.03
- MACD
- GOSS 0.01
- TSI -0.00
- Stochastic Oscillator
- GOSS 30.48
- TSI 33.33
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.